TrialDiabetic medicine : a journal of the British Diabetic Association2009

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).

M Marre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.